HEUKING advises Cologne-based BioTech start-up Detechgene on its Seed II financing round

Detechgene GmbH, an innovative BioTech start-up based in Cologne, has successfully completed its second seed financing round, raising a total of EUR 3 million. The company plans to use the fresh capital to further advance its vision of making molecular diagnostics mobile, fast, and reliable for everyone.

The round was led by Neoteq Ventures, an experienced early-stage investor focusing on technology-driven start-ups. In addition to NRW.BANK, Aquarius Invest GmbH, Meerkat Holding GmbH, Campus Capital, and several strategic business angels also participated. They not only contribute capital, but also valuable industry experience and networks. 

Detechgene was founded in 2022 by Dr. Reza Esmaillie and Dr. Robin Bayer. The company develops mobile rapid molecular biology tests that combine the precision of classic PCR methods with the user-friendliness of rapid antigen tests. With its PCR to Go system and DetechStamp and DetechChip products, Detechgene offers solutions that enable fast and accurate diagnostics directly at the point of care – independently of centralized laboratories.

“We are very grateful to our investors for their confidence in our team and our technology. Together, we are shaping the future of diagnostics – faster, more decentralised and more user-friendly than ever before”, says Dr. Reza Esmaillie, Managing Director of Detechgene.

The start-up was legally supported by HEUKING around Michael Kuska, LL.M., LL.M. (IP, Media & Technology / Düsseldorf), Dr. Patrick Müller (M&A/VC / Düsseldorf) and Sebastian Pollmeier (M&A/VC / Munich). HEUKING regularly advises start-ups and VC investors in various financing rounds.

Counsel to Detechgene GmbH
HEUKING:
Michael Kuska, LL.M., LL.M. (Lead, IP, Media & Technology),
Dr. Patrick Müller, LL.M. (University of the West of England, Bristol), both Düsseldorf,
Sebastian Pollmeier (both Venture Capital), Munich